276 related articles for article (PubMed ID: 24736236)
1. Atherogenic dyslipidemia and residual cardiovascular risk in statin-treated patients.
Sirimarco G; Labreuche J; Bruckert E; Goldstein LB; Fox KM; Rothwell PM; Amarenco P;
Stroke; 2014 May; 45(5):1429-36. PubMed ID: 24736236
[TBL] [Abstract][Full Text] [Related]
2. Risk of stroke and cardiovascular events after ischemic stroke or transient ischemic attack in patients with type 2 diabetes or metabolic syndrome: secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial.
Callahan A; Amarenco P; Goldstein LB; Sillesen H; Messig M; Samsa GP; Altafullah I; Ledbetter LY; MacLeod MJ; Scott R; Hennerici M; Zivin JA; Welch KM;
Arch Neurol; 2011 Oct; 68(10):1245-51. PubMed ID: 21670382
[TBL] [Abstract][Full Text] [Related]
3. Baseline blood pressure, low- and high-density lipoproteins, and triglycerides and the risk of vascular events in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial.
Amarenco P; Goldstein LB; Callahan A; Sillesen H; Hennerici MG; O'Neill BJ; Rudolph AE; Simunovic L; Zivin JA; Welch KM;
Atherosclerosis; 2009 Jun; 204(2):515-20. PubMed ID: 18962621
[TBL] [Abstract][Full Text] [Related]
4. Usefulness of atherogenic dyslipidemia for predicting cardiovascular risk in patients with angiographically defined coronary artery disease.
Arca M; Montali A; Valiante S; Campagna F; Pigna G; Paoletti V; Antonini R; Barillà F; Tanzilli G; Vestri A; Gaudio C
Am J Cardiol; 2007 Nov; 100(10):1511-6. PubMed ID: 17996510
[TBL] [Abstract][Full Text] [Related]
5. Atherogenic Dyslipidemia and Residual Vascular Risk After Stroke or Transient Ischemic Attack.
Hoshino T; Ishizuka K; Toi S; Mizuno T; Nishimura A; Takahashi S; Wako S; Kitagawa K
Stroke; 2022 Jan; 53(1):79-86. PubMed ID: 34470483
[TBL] [Abstract][Full Text] [Related]
6. "If it ain't broke, don't fix it": a commentary on the positive-negative results of the ACCORD Lipid study.
Tenenbaum A; Fisman EZ
Cardiovasc Diabetol; 2010 Jun; 9():24. PubMed ID: 20550659
[TBL] [Abstract][Full Text] [Related]
7. Levels and changes of HDL cholesterol and apolipoprotein A-I in relation to risk of cardiovascular events among statin-treated patients: a meta-analysis.
Boekholdt SM; Arsenault BJ; Hovingh GK; Mora S; Pedersen TR; Larosa JC; Welch KM; Amarenco P; Demicco DA; Tonkin AM; Sullivan DR; Kirby A; Colhoun HM; Hitman GA; Betteridge DJ; Durrington PN; Clearfield MB; Downs JR; Gotto AM; Ridker PM; Kastelein JJ
Circulation; 2013 Oct; 128(14):1504-12. PubMed ID: 23965489
[TBL] [Abstract][Full Text] [Related]
8. Atorvastatin reduces the risk of cardiovascular events in patients with carotid atherosclerosis: a secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial.
Sillesen H; Amarenco P; Hennerici MG; Callahan A; Goldstein LB; Zivin J; Messig M; Welch KM;
Stroke; 2008 Dec; 39(12):3297-302. PubMed ID: 18845807
[TBL] [Abstract][Full Text] [Related]
9. The role of niacin in raising high-density lipoprotein cholesterol to reduce cardiovascular events in patients with atherosclerotic cardiovascular disease and optimally treated low-density lipoprotein cholesterol: baseline characteristics of study participants. The Atherothrombosis Intervention in Metabolic syndrome with low HDL/high triglycerides: impact on Global Health outcomes (AIM-HIGH) trial.
AIM-HIGH Investigators
Am Heart J; 2011 Mar; 161(3):538-43. PubMed ID: 21392609
[TBL] [Abstract][Full Text] [Related]
10. Triglyceride-Rich Lipoprotein Cholesterol and Risk of Cardiovascular Events Among Patients Receiving Statin Therapy in the TNT Trial.
Vallejo-Vaz AJ; Fayyad R; Boekholdt SM; Hovingh GK; Kastelein JJ; Melamed S; Barter P; Waters DD; Ray KK
Circulation; 2018 Aug; 138(8):770-781. PubMed ID: 29618599
[TBL] [Abstract][Full Text] [Related]
11. High Triglycerides Are Associated With Increased Cardiovascular Events, Medical Costs, and Resource Use: A Real-World Administrative Claims Analysis of Statin-Treated Patients With High Residual Cardiovascular Risk.
Toth PP; Granowitz C; Hull M; Liassou D; Anderson A; Philip S
J Am Heart Assoc; 2018 Aug; 7(15):e008740. PubMed ID: 30371242
[TBL] [Abstract][Full Text] [Related]
12. Effect of high-dose atorvastatin on renal function in subjects with stroke or transient ischemic attack in the SPARCL trial.
Amarenco P; Callahan A; Campese VM; Goldstein LB; Hennerici MG; Messig M; Sillesen H; Welch KM; Wilson DJ; Zivin JA
Stroke; 2014 Oct; 45(10):2974-82. PubMed ID: 25147328
[TBL] [Abstract][Full Text] [Related]
13. Oxidized Phospholipids on Apolipoprotein B-100 and Recurrent Ischemic Events Following Stroke or Transient Ischemic Attack.
Byun YS; Yang X; Bao W; DeMicco D; Laskey R; Witztum JL; Tsimikas S;
J Am Coll Cardiol; 2017 Jan; 69(2):147-158. PubMed ID: 28081824
[TBL] [Abstract][Full Text] [Related]
14. Atherogenic dyslipidemia in patients with transient ischemic attack.
Sirimarco G; Deplanque D; Lavallée PC; Labreuche J; Meseguer E; Cabrejo L; Guidoux C; Olivot JM; Abboud H; Lapergue B; Klein IF; Mazighi M; Touboul PJ; Bruckert E; Amarenco P
Stroke; 2011 Aug; 42(8):2131-7. PubMed ID: 21737806
[TBL] [Abstract][Full Text] [Related]
15. Atorvastatin in stroke: a review of SPARCL and subgroup analysis.
Huisa BN; Stemer AB; Zivin JA
Vasc Health Risk Manag; 2010 Apr; 6():229-36. PubMed ID: 20407630
[TBL] [Abstract][Full Text] [Related]
16. Residual dyslipidemia according to low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B among statin-treated US adults: National Health and Nutrition Examination Survey 2009-2010.
Wong ND; Chuang J; Zhao Y; Rosenblit PD
J Clin Lipidol; 2015; 9(4):525-32. PubMed ID: 26228670
[TBL] [Abstract][Full Text] [Related]
17. [Statins in the secondary prevention of stroke: New evidence from the SPARCL Study].
Castilla-Guerra L; Fernández-Moreno Mdel C; López-Chozas JM
Clin Investig Arterioscler; 2016; 28(4):202-8. PubMed ID: 26150172
[TBL] [Abstract][Full Text] [Related]
18. On-treatment non-high-density lipoprotein cholesterol, apolipoprotein B, triglycerides, and lipid ratios in relation to residual vascular risk after treatment with potent statin therapy: JUPITER (justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin).
Mora S; Glynn RJ; Boekholdt SM; Nordestgaard BG; Kastelein JJ; Ridker PM
J Am Coll Cardiol; 2012 Apr; 59(17):1521-8. PubMed ID: 22516441
[TBL] [Abstract][Full Text] [Related]
19. Rationale and design of a randomized, double-blind, parallel-group study of terutroban 30 mg/day versus aspirin 100 mg/day in stroke patients: the prevention of cerebrovascular and cardiovascular events of ischemic origin with terutroban in patients with a history of ischemic stroke or transient ischemic attack (PERFORM) study.
Bousser MG; Amarenco P; Chamorro A; Fisher M; Ford I; Fox K; Hennerici MG; Mattle HP; Rothwell PM;
Cerebrovasc Dis; 2009; 27(5):509-18. PubMed ID: 19372653
[TBL] [Abstract][Full Text] [Related]
20. Lowering Targeted Atherogenic Lipoprotein Cholesterol Goals for Patients at "Extreme" ASCVD Risk.
Rosenblit PD
Curr Diab Rep; 2019 Nov; 19(12):146. PubMed ID: 31754844
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
